Investment Theme
Medical Devices
Devices that improve patient outcomes or create a new standard of care, from diagnostics-adjacent hardware to implantables and surgical tools.
The Space
Medical device investing runs on a different clock than therapeutics: the regulatory path is often shorter, but the engineering, manufacturing, and reimbursement questions arrive earlier and matter just as much as the clinical evidence.
A device company can have compelling bench data and still be a hard investment if the path to a defensible regulatory clearance, a scalable manufacturing process, and a payer or provider willing to adopt it hasn’t been thought through.
Why It Matters
The gap between promising and investable.
The device space rewards founders who can hold engineering, clinical, and commercial questions at once, because a device that works in a lab but cannot be manufactured at the tolerances or cost the business model needs is not yet a company.
ChaosBio looks for teams that have already had the hard manufacturing and reimbursement conversations, not ones that are planning to have them after the raise.
The ChaosBio Lens
What ChaosBio looks for.
Applied to every medical devices opportunity ChaosBio reviews, alongside the general investment framework.
Clinical differentiation
Does the device create a measurable improvement in outcome, workflow, or cost over the current standard of care, not just a novel form factor?
Regulatory route
Is the classification and predicate strategy (or de novo path) understood well enough to estimate cost and timeline with real confidence?
Manufacturing and scale-up
Has the team addressed the questions that surface late — tolerances, suppliers, and cost of goods — early enough that they do not become preventable surprises?
Adoption and reimbursement
Is there a credible path to the clinician, health system, or payer actually adopting and paying for this, not just approving it?
Portfolio
Companies ChaosBio has backed in this space.
Related Reading
From the Journal.
See medical devices opportunities as they come in.
Join the Investor Network for curated medical devices and other early-stage life sciences opportunities, reviewed through the ChaosBio investment framework. Free, and no obligation to invest.